Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 2

The procedure guidelines for radioiodine therapy (RIT) of differentiated thyroid cancer (version 2) are the counterpart to the procedure guidelines for 131I whole-body scintigraphy (version 2) and specify the interdisciplinary guidelines for thyroid cancer of the Deutsche Krebsgesellschaft and the Deutsche Gesellschaft fur Chirurgie concerning the nuclear medicine part. Compared with version 1 facultative options for RIT can be chosen in special cases: ablative RIT for papillary microcarcinoma ≤1 cm, ablative RIT for mixed forms of anaplastic and differentiated thyroid cancer, and RIT in patients with a measurable or increasing thyroglobulin concentration but without detectable metastases by imaging. The description of the pretherapeutic dosimetry now includes the isotopes 123I and 124I as well as a broader range of the activity of 131I. Activities of 2-5 GBq 131I are recommended for the first ablative RIT. If high accumulative activities of 131I are expected, men who have not yet finished their family planning should be advised to the option of sperm cryoconservation. An interdisciplinary consensus is necessary whether the new TNM-classification (UICC, 6th edition, 2002) will lead to modified recommendations for surgical or nuclear medicine therapy, especially for the surgical completeness and for the ablative RIT of pT1 papillary cancer.

[1]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[2]  M. Gotthardt,et al.  Decrease of 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s , 2006, Nuklearmedizin.

[3]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[4]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[5]  H. Holzhausen,et al.  The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma , 2005, Cancer.

[6]  N. Tamaki,et al.  Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  N. Willich,et al.  Acute Toxicity of Adjuvant Radiotherapy in Locally Advanced Differentiated Thyroid Carcinoma , 2003, Strahlentherapie und Onkologie.

[8]  A. Alessi,et al.  FDG-PET in Thyroid Cancer , 2003, Tumori.

[9]  C. Reiners,et al.  Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2) , 2003, Nuklearmedizin.

[10]  C. Reiners,et al.  Procedure guideline for radioiodine test (version 2) , 2003, Nuklearmedizin.

[11]  C. Reiners.  Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  T. Petrich,et al.  Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  M. Wichers,et al.  Testicular function after radioiodine therapy for thyroid carcinoma , 2000, European Journal of Nuclear Medicine.

[14]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[15]  O. Schober,et al.  Survival of differentiated thyroid carcinoma studied in 500 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Pinchera,et al.  Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  G. Johnston,et al.  Radioiodine therapy for thyroid cancer. , 1995, Endocrinology and metabolism clinics of North America.

[18]  E. Genina,et al.  Diagnostic 123I and 131I activities and radioiodine therapy , 2005, Nuklearmedizin.

[19]  M. Seyfarth,et al.  Reduced radioiodine uptake at increased iodine intake and 131I-induced release of “cold” iodine stored in the thyroid , 2005, Nuklearmedizin.

[20]  M. Dietlein,et al.  Leitlinie* zur Schilddrüsendiagnostik (Version 2**) , 2003 .

[21]  M. Wucherer.  Richtlinie Strahlenschutz in der Medizin 2002 , 2003 .

[22]  H. Elser.  Therapie mit offenen radioaktiven Stoffen , 2003 .

[23]  P. Lind.  Should high hTg levels in the absence of iodine uptake be treated? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  D. Simon.  Redifferentiation Therapy of Thyroid Carcinomas with Retinoic Acid , 2001 .

[25]  F. Grünwald.  Functional Imaging of Thyroid Cancer , 2001 .